Dr. Morris on the significance of the emergence of 177Lu-PSMA-617 in prostate cancer

Michael J. Morris, MD, discusses the rise of radiopharmaceuticals in prostate cancer and, in particular, the success of 177Lu-PSMA-617 (LuPSMA). Data from the phase 3 VISION trial presented at the 2021 ASCO Annual Meeting showed that adding Lu-PSMA-617 to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. Morris, a medical oncologist and section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, was the lead study author on the VISION trial (J Clin Oncol 39, 2021 [suppl 15; abstr LBA4]).

Related Videos
Madison Novosel, BA, in an interview with Urology Times
Veda Giri, MD, answers a question during a Zoom video interview
Dr. Bertrand F. Tombal in an interview with Urology Times
Related Content
© 2023 MJH Life Sciences

All rights reserved.